Background: Almost all deaths from breast cancer are due to metastasis. People living with metastatic breast cancer (MBC) and their loved ones have been concerned about the lack of research progress. The purposes of this paper were to analyze breast cancer research spending in Canada, and to evaluate whether MBC research was aligned with patient priorities. The results from the MBC Priority Setting Partnership (MBC PSP) were used as an approximation of patient priorities.
Methods: The data source was the Canadian Cancer Research Survey. MBC projects were identified and mapped to the patient priorities.
Results: This analysis found that 18% of breast cancer research investment was directed to MBC, with a large proportion of this research investment focused on the biology of metastasis. Four of the top 10 MBC PSP priorities had not been addressed: optimal sequence of therapy, role of continuous versus intermittent treatment, benefits of early palliative care, and best methods for patient education.
Conclusion: These figures provide a baseline from which any increases in MBC research and improved alignment to patient priorities can be measured. A cooperative effort by funders, researchers, patients, caregivers, and health care providers is needed to address research gaps.
Full text article
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-15.
Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199-E205.
Nixon NA, Simmons C, Lemieux J, Verma S. Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership. Breast J. 2020;26(3):488-93.
Canadian Cancer Research Alliance. Toronto (ON): Canadian Cancer Research Alliance; c2020. Reports. [Available from: https://www.ccra-acrc.ca/reports/ ]
International Cancer Research Partnership. Common Scientific Outcome. Available from: [Available from:https://www.icrpartnership. org/cso ]
Metastatic Breast Cancer Alliance. Metastatic Breast Cancer Landscape Analysis: Research Report. [Internet] New York (NY): Metastatic Breast Cancer Alliance; 2014: 132. [Available from: https://www.mbcalliance.org/wp-content/uploads/Chapter-2-1.pdf]
Perkins J, editor An analysis of the National Institutes of Health (NIH) breast cancer research portfolio and the Department of Defense (DOD) breast cancer research program (BCRP) funding for metastatic breast cancer research in fiscal year 2016. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res.
Flowers M, Reffey SB, Mertz SA, Hurlbert M. Obstacles, opportunities and priorities for advancing metastatic breast cancer research. Cancer research. 2017;77(13):3386-90.
Stand up to Cancer Canada. Toronto (ON): Stand up to Cancer Canada; c2020. [Available from: https://standuptocancer.ca/ press-releases/stand-up-to-cancer-canada-canadian-cancer-society-canadian-institutes-of-health-research-announce-dream-team-focused-on-new-approach-to-metastatic-breast-cancer/.]
Cancer Research Society. Montréal (QC): Cancer Research Society; c2021. 100 Years of Cancer Research. [Available from: https://www. societederecherchesurlecancer.ca/en/researchers/100-ans-de-recherche-sur-le-cancer]
Pfizer Canada . Kirkland (QC): Pfizer Canada; c2020. Helping Communities. [Available from: https://www.pfizer.ca/pfizer-canada-announces-launch-joint-request-proposals-rfp-partnership-rethink-breast-cancer.]
Copyright (c) 2021 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.